Showing results (211-220 of 509) with videos related to

Sort By:
Pageof 51
The American Journal of Emergency Medicine|May 26, 2005
Population-based study of police-reported sexual assault in Baltimore, MarylandKathleen M Read, Joseph A Kufera, M Christine Jackson, et al.
Accident; Analysis and Prevention|January 24, 2006
Risk perception and impulsivity: association with risky behaviors and substance abuse disordersGabriel E Ryb, Patricia C Dischinger, Joseph A Kufera, et al.
Trauma, Violence & Abuse|July 12, 2025
The Factors That Contribute to Dysfunctional Behavior in Active Military Personnel: An Umbrella ReviewJolene A Cox, Scott McLean, Gemma J M Read, et al.
Pediatric Pulmonology|September 6, 2012
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodiumDavid C Young, Jeffery T Zobell, C Dustin Waters, et al.
Clinical Pharmacokinetics|May 30, 2014
Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infantsJessica K Roberts, Chris Stockmann, Jonathan E Constance, et al.
Clinical Pharmacokinetics|May 21, 2015
Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic EncephalopathyJessica K Roberts, Chris Stockmann, Robert M Ward, et al.
The AAPS Journal|May 30, 2019
Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in NeonatesWojciech Krzyzanski, Sarah F Cook, Melanie Wilbaux, et al.
Pediatric Pulmonology|September 6, 2012
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillinsJeffery T Zobell, C Dustin Waters, David C Young, et al.
Pediatric Pulmonology|August 23, 2012
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenemsJeffery T Zobell, David C Young, C Dustin Waters, et al.
Pediatric Pulmonology|January 30, 2013
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summaryJeffery T Zobell, David C Young, C Dustin Waters, et al.
Pageof 51